Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Largo Professor Abel Salazar, 2, 4099-003 Porto, Portugal.
Vet J. 2011 Jul;189(1):43-8. doi: 10.1016/j.tvjl.2010.05.023. Epub 2010 Jul 2.
Urokinase plasminogen activator (uPA) has been associated with aggressive behaviour and poor prognosis in human breast cancer, but there is no information on its expression in canine mammary tumours (CMT). uPA immunohistochemical expression was studied in 119 CMT (24 benign, 95 malignant) to investigate its relationship with clinical and histopathological parameters. Dogs with malignant mammary tumours (MMT) underwent a 2-year follow-up evaluation. MMT expressed significantly more uPA than benign tumours. In MMT, high uPA stromal expression was significantly associated with larger tumour size, high Ki-67 expression, invasive growth, high histological grade, regional lymph node metastases, development of distant metastases, and lower overall survival (OS) and disease-free survival (DFS). On the basis of these results, uPA could be considered a useful prognostic factor in dogs with MMT.
尿激酶型纤溶酶原激活物（uPA）与人类乳腺癌的侵袭性行为和不良预后相关，但犬乳腺肿瘤（CMT）中其表达情况尚无信息。本研究检测了 119 例 CMT（24 例良性，95 例恶性）中 uPA 的免疫组织化学表达，以研究其与临床和组织病理学参数的关系。对患有恶性乳腺肿瘤（MMT）的狗进行了 2 年的随访评估。结果显示，MMT 表达的 uPA 明显多于良性肿瘤。在 MMT 中，较高的 uPA 基质表达与肿瘤体积较大、Ki-67 表达较高、浸润性生长、组织学分级较高、区域淋巴结转移、远处转移发展以及总生存（OS）和无病生存（DFS）较低显著相关。基于这些结果，uPA 可被视为 MMT 狗的一种有用的预后因素。
